^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRCA wild-type

    i
    Other names: BRCA1, BRCC1, PPP1R53, RNF53, Breast cancer 1, early onset, BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset
    Entrez ID:
    672; 675
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    10ms
    Second-line maintenance therapy with niraparib improved overall survival vs active surveillance in patients with recurrent BRCA wild-type ovarian cancer. @rcoledude #ovca #ASCO23 https://t.co/MNEYhPArVr (@OncLive)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA wild-type
    |
    Zejula (niraparib)
    10ms
    Second-line maintenance therapy with niraparib improved overall survival vs active surveillance in patients with recurrent BRCA wild-type ovarian cancer. @rcoledude #ovca #ASCO23 https://t.co/Ggf2NEur0I (@OncLive)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA wild-type
    |
    Zejula (niraparib)
    1year
    True mCRPC pts are dwindling as most of them are started on ADT + NHT. For second line progression - BRCA/ CHEK2 m-> switch to single agent PARPi vs add it on top of NHT? For BRCA WT -Add PARPi and continue NHT? (@RenoHemonc)
    Clinical
    |
    BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2)
    |
    BRCA wild-type
    1year
    Question for the experts: 54 yo woman with right TNBC pT2N1M0, BRCA wt. Met her after surgery 😒. @hoperugo @darioT_ @PTarantinoMD @Dr_RShatsky @fnacevedo @CesarGSanchezR @SuyogCancer (@benjiwal)
    Surgery
    |
    BRCA (Breast cancer early onset)
    |
    BRCA wild-type
    over1year
    I do think in the TNBC, wild type BRCA space that have high TMB the use of immunotherapy has been disappointing. This is the space that clearly needs to most amount of work. (@DrARS77)
    TMB (Tumor Mutational Burden) • BRCA (Breast cancer early onset)
    |
    TMB-H • BRCA wild-type
    over1year
    A phase II trial shows promising results with the PARP ihibitor talazoparib in patients with wild-type BRCA1/2 advanced #breastcancer https://t.co/J8nPPVWJ4b #fondazionebonadonna #oncology #cancerreseach @BianchiniGP @mauricallari @CarmenCriscit (@FondazioneBona1)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    BRCA wild-type
    |
    Talzenna (talazoparib)
    over1year
    12/18 #TumorBoardTuesday #BCSM 🌟We are now in the realm of ADCs! Because our 👩🏾 was: 🧬gBRCA wild type 🔬Her2 1+ 🔥#ProTip 👉🏽This is when I would send off genomic profiling if I hadn’t already. Then I have it. If I have a 🦄, I am ready to consider those agents in 3rd Line (@LauraSalamaMD)
    HER-2 (Human epidermal growth factor receptor 2)
    |
    BRCA wild-type
    over1year
    @seemagulia1 @TataMemorial publish the only IPD metaanalysis PARP-inhibitors first-line ovarian cancer! Highly impactful results, clear benefit BRCA-mut or HRD-pos pts, but NOT in BRCA-wt/HRD-neg pts! @jamecancerdoc @AnaOaknin @myESMO @ASCOPost @sujithonco https://t.co/eXGgl26gAt (@ACTREC_TMC)
    Retrospective data
    |
    BRCA (Breast cancer early onset)
    |
    BRCA wild-type
    almost2years
    Excited to see if BET + PARP can sensitize BRCA wt tumors to talazoparib. Looking at pts who have seen saci as well. #ASCO22 #bcsm (@ErikaHamilton9)
    Clinical
    |
    BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    BRCA wild-type
    |
    Talzenna (talazoparib)